Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 916

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Candidate mechanisms for chemotherapy-induced cognitive changes

Open access
Ahles, Tim A., Saykin, Andrew J.·2007·Nature Reviews Cancer
DOI 10.1038/nrc2073
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/nrc2073

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 101

  1. Silberfarb, P. M. Chemotherapy and cognitive defects in cancer patients. Annu. Rev. Med. 34, 35–46 (1983). · DOI
  2. Wieneke, M. H. & Dienst, E. R. Neuropsychological assessment of cognitive functioning following chemotherapy for breast cancer. Psychooncology 4, 61–66 (1995). · DOI · Paper page
  3. van Dam, F. S. et al. Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy. [comment]. J. Natl Cancer Inst. 90, 210–218 (1998). · DOI
  4. Schagen, S. B. et al. Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma. Cancer 85, 640–650 (1999). · DOI
  5. Brezden, C. B. et al. Cognitive function in breast cancer patients receiving adjuvant chemotherapy. J. Clin. Oncol. 18, 2695–2701 (2000). · DOI
  6. Ahles, T. A. et al. Neuropsychological impact of standard-dose chemotherapy in long-term survivors of breast cancer and lymphoma. J. Clin. Oncol. 20, 485–493 (2002). · DOI
  7. Tchen, M. et al. Cognitive function, fatigue, and menopausal symptoms in women receiving adjuvant chemotherapy for breast cancer. J. Clin. Oncol. 21, 4175–4183 (2003). · DOI
  8. Castellon, S. A. et al. Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen. J. Clin. Exp. Neuropsychol. 26, 955–969 (2004). · DOI
  9. Wefel, J. S. et al. The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: results of a prospective, randomized, longitudinal trial. Cancer 100, 2292–2299 (2004). · DOI
  10. Schilling, V. et al. The effects of adjuvant chemotherapy on cognition in women with breast cancer — preliminary results of an observational study. The Breast 14, 142–150 (2005). · DOI
  11. Jenkins, V. et al. A 3-year prospective study of the effects of adjuvant treatments on cognition in women with early stage breast cancer. Br. J. Cancer 94, 828–834 (2006). · DOI
  12. Donovan, K. A. et al. Cognitive functioning after adjuvant chemotherapy and/or radiotherapy for early stage breast carcinoma. Cancer 104, 2499–2507 (2005). · DOI
  13. Tannock, I. F., Ahles, T. A., Ganz, P. A. & van Dam, F. S. Cognitive impairment associated with chemotherapy for cancer: report of a workshop. J. Clin. Oncol. 22, 2233–2239 (2004). This paper provides an overview of a consensus conference that included most of the researchers from around the world who were conducting research on chemotherapy-induced cognitive changes. · DOI
  14. Ahles, T. A. & Saykin, A. J. Breast cancer chemotherapy-related cognitive dysfunction. Clin. Breast Cancer Suppl. 3, S84–S90 (2002). · DOI
  15. Ferguson, R. J. & Ahles, T. A. Low neuropsychologic performance among adult cancer survivors treated with chemotherapy. Curr. Neurol. Neurosci. Rep. 3, 215–222 (2003). · DOI
  16. Anderson-Hanley, C., Sherman, M. L., Riggs, R. Agocha, V. V. & Compas, B. E. Neuropsychological effects of treatments for adults with cancer: A meta-analysis and review of the literature. J. Int. Neuropsychol. Soc. 9, 967–982 (2003). · DOI
  17. Saykin, A. J., Ahles, T. A. & McDonald, B. C. Mechanisms of chemotherapy-induced cognitive disorders: neuropsychological, pathophysiological and neuroimaging perspectives. Sem. Clin. Neuropsych. 8, 201–216 (2003). · DOI
  18. Stemmer, S. et al. White matter changes in patients with breast cancer treated with high-dose chemotherapy and autologous bone marrow support. Am. J. Neuroradiol. 15, 1267–1273 (1994).
  19. Saykin, A. J. et al. Altered brain activation following systemic chemotherapy for breast cancer: interim analysis from a prospective study. J. Int. Neuropsychol. Soc. 12, 131 (2006).
  20. Kreukels, B. P. et al. Electrophysiological correlates of information processing in breast-cancer patients treated with chemotherapy. Breast Cancer Res. Treat. 94, 53–61 (2005). · DOI
  21. Kreukels, B. P. et al. Effects of high-dose and conventional-dose adjuvant chemotherapy on long-term cognitive sequelae in patients with breast cancer: an electrophysiologic study. Clin. Breast Cancer 7, 67–78 (2006). · DOI
  22. Wefel, J. S. et al. Chemobrain in breast carcinoma? A prologue. Cancer 101, 466–475 (2004). · DOI
  23. Meyers, C. A., Albitar M. & Estey, E. Cognitive impairment, fatigue, and cytokine levels in patients with acute myelogenous leukemia or myelodysplastic syndrome. Cancer 104, 788–793 (2005). · DOI
  24. Ahles, T. A. et al. Psychological and neuropsychological functioning of patients with limited small-cell lung cancer treated with chemotherapy and radiation therapy with or without warfarin, a study for Cancer and Leukemia Group B. J. Clin. Oncol. 16, 1954–1960 (1998). · DOI
  25. Wagner, L. I. et al. Trajectory of cognitive impairment during breast cancer treatment: a prospective analysis. J. Clin. Oncol. Suppl. 24, 8500 (2006). · DOI
  26. Heflin, L. H. et al. Cancer as a risk factor for long-term cognitive deficits and dementia. J. Natl Cancer Inst. 97, 854–856 (2005). · DOI
  27. Verstappen C. C. P., Heimans, J. J., Hoekman, K. & Postma T. J. Neurotoxic complications of chemotherapy in patients with cancer: Clinical signs and optimal management. Drugs 63, 1549–1563 (2003). · DOI
  28. Troy, L. et al. Cisplatin-based therapy: A neurological and neuropsychological review. Psychooncology 9, 29–39 (2000). · DOI
  29. Ginos J. Z. et al. [13N]cisplatin PET to assess pharmacokinetics of intro-arterial versus intravenous chemotherapy for malignant brain tumors. J. Nucl. Med. 28, 1844–1852 (1987).
  30. Mitsuki, S. et al. Pharmacokinetics of 11C-labelled BCNU and SARCNU in gliomas studied by PET. J.Neurooncol. 10, 47–55 (1991). · DOI
  31. Gangloff, A. et al. Estimation of paclitaxel biodistribution and uptake in human-derived xenografts in vivo with 18F-Fluoropaclitaxel. J. Nucl. Med. 46, 1866–1871 (2005).
  32. Dietrich, J., Han, R., Yang, Y., Mayer-Proschel, M. & Noble, M. CNS progenitor cells and oligodendrocytes are targets of chemotherapeutic agents in vitro and in vivo. J. Biol. 5, 22 [Epub ahead of print] (2006). This is an excellent paper describing in vitro and in vivo (mice) studies showing that common chemotherapy agents caused increased cell death and decreased cell division in the subventricular zone and in the dentate gyrus of the hippocampus, and in the corpus callosum. These effects were seen with doses that were not effective in causing cell death in tumor cell lines. · DOI
  33. Jamroziak, K. & Robak, T. Pharmacogenomics of MDR1/ABCB1 gene: the influence on risk and clinical outcome of haematological malignancies. Hematology 9, 91–105 (2004). · DOI
  34. Hoffmeyer, S. et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl Acad. Sci. USA 97, 3473–3478 (2000). · DOI · Paper page
  35. Kreb, R. Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett. 234, 4–33 (2006). This manuscript describes evidence for genetic variability in drug transporters and their influence on drug disposition and clinical response. · DOI
  36. Muramatsu, T. et al. Age-related differences in vincristine toxicity and biodistribution in wild-type and transporter-deficient mice. Oncol. Res. 14, 331–343 (2004). · DOI
  37. Uhr, M., Holsboer, F. & Muller, M. B. Penetration of endogenous steroid hormones corticosterone, cortisol, aldosterone and progesterone into the brain is enhanced in mice deficient for both mdr1a and mdr1b p-glycoproteins. J. Neuroendocrinol. 14, 753–759 (2002). · DOI
  38. Rolig, R. L. & McKinnon, P. J. Linking DNA damage and neurodegeneration. Trends Neurosci. 23, 417–424 (2000). This paper provides an overview of the evidence linking DNA damage to neurodegeneration and cognitive function. · DOI
  39. Goode, E. L., Ulrich, C. M. & Potter, J. D. Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol. Biomarkers Prev. 11, 1513–1530 (2002).
  40. Caldecott, K. W. DNA single-strand breaks and neurodegeneration. DNA Repair 3, 875–882 (2004). · DOI
  41. Abner, C. W. & McKinnon, P. J. The DNA double-strand break response in the nervous system. DNA Repair 3, 1141–1147 (2004). · DOI
  42. Fishel, M. L., Vasko, M. R. & Kelley, M. R. DNA repair in neurons: so if they don't divide what's to repair? Mutat. Res. 614, 24–36 (2007). This paper reviews the relevance of DNA-repair pathways to DNA damage in post-mitotic neurons, and the impact of DNA damage on neuronal survival and brain ageing. Additionally, these authors relate DNA repair to neurotoxicity associated with chemotherapy, including cognitive side effects and peripheral neuropathy. · DOI
  43. Sedletska, Y., Giraud-Panis, M.-J. & Malinge, J.-M. Cisplatin is a DNA-damaging antitumour coumpound triggering multifactorial biochemical responses in cancer cells: Importance of apoptotic pathways. Curr. Med. Chem. Anticancer Agents 5, 251–265 (2005). · DOI
  44. Blasiak J. et al. Basal, oxidative and alkylative DNA damage, DNA repair efficacy and mutagen sensitivity in breast cancer. Mutat. Res. 554, 139–148 (2004). Using the comet assay, these investigators showed greater DNA damage and lower DNA repair efficacy in patients with breast cancer, both before and after chemotherapy. · DOI
  45. Nadin S. B., Vargas-Roig, L. M., Drago, G., Ibarra, J. & Ciocca, D. R. DNA damage and repair in peripheral blood lymphocytes from healthy individuals and cancer patients: a pilot study on the implications in response to chemotherapy. Cancer Lett. 239, 84–87 (2006). · DOI
  46. Wardell, T. M. et al. Changes in human mitochondrial genome after treatment of malignant disease. Mutat. Res. 525, 19–27 (2003). · DOI
  47. Weijl, N. I. et al. Non-protein bound iron release during chemotherapy in cancer patients. Clin. Sci. 106, 475–484 (2004). · DOI
  48. Kaya, E. et al. Oxidant/antioxidant parameters and their relationship with chemotherapy in Hodgkin's lymphoma. J. Int. Med. Res. 33, 687–692 (2005). · DOI
  49. Papageorgiou, M. et al. Cancer chemotherapy reduces plasma total antioxidant capacity in children with malignancies. Leukemia Res. 29, 11–16 (2005). · DOI
  50. Kennedy, D. D., Ladas, E. J., Rheingold, S. R., Blumberg, J. & Kelly, K. M. Antioxidant status decreases in children with acute lymphoblastic leukemia during the first six months of chemotherapy treatment. Ped. Blood Cancer 44, 378–385 (2005). · DOI
  51. Mariani, E., Polidori, M. C., Cherubini, A. & Mecocci, P. Oxidative stress in brain aging, neurodegenerative and vascular diseases: an overview. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 827, 65–75 (2005). · DOI
  52. Migliore, L. et al. Oxidative DNA damage in peripheral leukocytes of mild cognitive impairment and AD patients. Neurobiol. Aging 26, 567–573 (2005). The results of this study showed that patients with mild cognitive impairment, a condition characterized by a relatively isolated impairment in memory in the context of normal functioning in other areas, had higher levels of DNA damage compared with older adults without mild cognitive impairment. · DOI
  53. Keller, J. N. et al. Evidence of increased oxidative damage in subjects with mild cognitive impairment. Neurology 64, 1152–1156 (2005). This study showed that patients who had been diagnosed with mild cognitive impairment had elevated levels of DNA damage in the brain at autopsy, suggesting a relationship between DNA damage seen peripherally in this population and DNA damage in the CNS. · DOI · Paper page
  54. Harrison, J. F. et al. Oxidative stress-induced apoptosis in neurons correlates with mitcochondrial DNA base exicision repair pathway imbalance. Nucleic Acids Res. 33, 4660–4671 (2005). · DOI
  55. Vajdovich, P. et al. Redox status in dogs with non-hodgkin lymphomas. An ESR study. Cancer Lett. 224, 339–346 (2005). · DOI
  56. Hung, R., Hall, J., Brennan, P. & Boffetta, P. Genetic polymorphisms in the base excision repair pathway and cancer risk: A HuGE review. Am. J. Epidemiol. 162, 925–942 (2005). · DOI
  57. von Zglinicki, T. & Martin-Ruiz, C. M. Telomeres as biomarkers for ageing and age-related diseases. Curr. Mol. Med. 5, 197–203 (2005). · DOI
  58. Vasa-Nicotera, M. et al. Mapping of a major locus that determines telomere length in humans. Am. J. Hum. Genet. 76, 147–151 (2005). · DOI · Paper page
  59. Schroder, C. P. et al. Telomere length in breast cancer patients before and after chemotherapy with or without stem cell transplation. Br. J. Cancer 84, 1348–1353 (2001). · DOI
  60. Lahav, M. et al. Nonmyeloablative conditioning does not prevent telomere shortening after allogeneic stem cell transplantation. Transplantation 80, 969–976 (2005). · DOI
  61. Maccormick, R. E. Possible acceleration of aging by adjuvant chemotherapy: a cause of early onset frailty? Med. Hypotheses 67, 212–215 (2006). This manuscript reviews the evidence that morbidity associated with chemotherapy might be related to acceleration of the ageing process. · DOI
  62. Flanary, B. E. & Streit, W. J. Progressive telomere shortening occurs in cultured rat microglia, but not astrocytes. Glia 45, 75–88 (2004). · DOI · Paper page
  63. Tonelli, L. H., Postolache, T. T. & Sternberg, E. M. Inflammatory genes and neural activity: involvement of immune genes in synaptic function and behavior. Front. Biosci. 10, 675–680 (2005). · DOI
  64. Cleeland, C. S. et al. Are the symptoms of cancer and cancer treatment due to a shared biologic mechanism? A cytokine-immunologic model of cancer symptoms. Cancer 97, 2919–2925 (2003). · DOI
  65. Kelley, K. W. et al. Cytokine-induced sickness behavior. Brain Behav. Immun. 17, S112–S118 (2003) · DOI · Paper page
  66. Maier, S. F. & Watkins L. R. Immune-to-central nervous system communication and its role in modulating pain and cognition: Implications for cancer and cancer treatments. Brain Behav. Immun. 17, S125–S131 (2003). · DOI
  67. Krabbe, K. S. et al. Low-dose endotoxemia and human neuropsychological functions. Brain Behav. Immun. 19, 453–460 (2005). · DOI · Paper page
  68. Trask, P. C., Esper, P., Riba, M. & Redman, B. Psychiatric side effects of interferon therapy: prevalence, proposed mechanisms, and future directions. J. Clin. Oncol. 18, 2316–2326 (2000). · DOI
  69. Scheibel, R. S., Valentine, A. D., O'Brien, S. & Meyers, C. A. Cognitive dysfunction and depression during treatment with interferon-α and chemotherapy. J.Neuropsych. Clin. Neurosci. 16, 185–191 (2004). · DOI
  70. Capuron, L., Ravaud, A. & Dantzer, R. Timing and specificity of the cognitive changes induced by interleukin-2 and interferon-α treatments in cancer patients. Psychosom. Med. 63, 376–386 (2001). · DOI · Paper page
  71. Pusztai, L. et al. Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy. Cytokine 25, 94–102 (2004). · DOI
  72. Penson, R. T. et al. Chtokines IL-1β, IL-2, IL-6, IL-8, MCP-1, GM-CSF and TNFα in patients with epithelial ovarian cancer and their relationship to treatment with paclitaxel. Int. J. Gynecol. Cancer 10, 33–41 (2000). · DOI
  73. Callado-Hidalgo, A., Bower, J. E., Ganz, P. A., Cole, S. W. & Irwin, M. R. Inflammatory biomarkers for persistent fatigue in breast cancer survivors. Clin. Cancer Res. 12, 2759–2766 · DOI
  74. Bower, J. E., Ganz, P. A., Aziz, N., Fahey, J. L. Fatigue and proinflammatory cytokine activity in breast cancer survivors. Psychosom. Med. 64, 604–611 (2002). · DOI
  75. Balkwill, F. & Mantovani, A. Inflammation and cancer: back to Virchow? Lancet 357, 539–545 (2001). · DOI · Paper page
  76. de Visser, K. E., Eichten, A. & Coussens, L. M. Paradoxical roles of the immune system during cancer development. Nature Rev. Cancer 6, 24–37 (2006). This paper presents evidence in support of a role for chronic inflammation in enhancing the predisposition to develop cancer. Furthermore, the authors present evidence that genetic polymorphisms that regulate immune function can affect cancer risk. · DOI
  77. McGeer, P. L. & McGeer, E. G. Polymorphisms in inflammatory genes and risk of Alzheimer Disease. Arch. Neurol. 58, 1790–1792 (2001). · DOI
  78. Morley, K. I. & Montgomery, G. W. The genetics of cognitive processes: candidate genes in humans and animals. Behav. Genet. 31, 511–531 (2001). · DOI
  79. Hartman, R. E. et al. Apolipoprotein E4 influences amyloid deposition but not cell loss after traumatic brain injury in a mouse model of Alzheimer's disease. J. Neurosci. 22, 10083–10087 (2002). · DOI · Paper page
  80. Sabo, T. et al. Susceptibility of transgenic mice expressing human apolipoprotein E to closed head injury: the allele E3 is neuroprotective whereas E4 increases fatalities. Neuroscience 101, 879–884 (2000). · DOI · Paper page
  81. Laws, S. M. et al. APOE-epsilon4 and APOE-491A polymorphisms in individuals with subjective memory loss. Mol. Psych. 7, 768–775 (2002). · DOI
  82. Nathoo, N. et al. Genetic vulnerability following traumatic brain injury: the role of apolipoprotein E. Mol. Pathol. 56, 132–136 (2003). · DOI
  83. Ahles, T. A., Saykin, A. J. & Noll, W. W. et al. The relationship of APOE genotype to neuropsychological performance in long-term cancer survivors treated with standard dose chemotherapy. Psychooncology 12, 612–619 (2003) This is the first study to show an association between APOE genotype and cognitive functioning in long-term cancer survivors. · DOI
  84. Lind, J. et al. Reduced hippocampal volume in non-demented carriers of the apolipoprotein E ɛ4: relation to chronological age and recognition memory. Neurosci. Lett. 396, 23–27 (2006). · DOI
  85. Pang, P. T. & Lu, B. Regulation of late-phase LTP and long-term memory in normal and ageing hippocampus: role of secreted proteins tPA and BDNF. Age. Res. Rev. 3, 407–430 (2004). · DOI
  86. Savitz, J., Solms, M. & Ramesar, R. The molecular genetics of cognition: dopamine, COMT, and BDNF. Genes Brain Behav. 5, 311–328 (2006). This paper provides an excellent review of the research examining the relationship between genetic variability and cognitive functioning with an emphasis on dopamine receptor genes, catechol-O-methyltransferase ( COMT ) and brain-derived neurotrophic factor ( BDNF). · DOI
  87. Hariri, A. R. et al. Brain-derived neurotrophic factor val66met polymorphism affects human memory-related hippocampal activity and predicts memory performance. J. Neurosci. 23, 6690–6694 (2003). · DOI · Paper page
  88. McAllister, T. W. et al. Cognitive effects of cytotoxic cancer chemotherapy: predisposing risk factors and potential treatments. Curr. Psych. Rep. 6, 364–371 (2004). · DOI
  89. Weinberger, D. R. et al. Prefrontal neurons and the genetics of schizophrenia. Biol. Psychiatry 50, 825–844 (2001). · DOI
  90. Malhotra, A. K. et al. A functional polymorphism in the COMT gene and performance on a test of prefrontal cognition. Am. J. Psych. 159, 652–654 (2001). · DOI
  91. Zec, R. F. & Trivedi, M. A. The effects of estrogen replacement therapy on neuropsychological functioning in postmenopausal women with and without dementia: a critical and theoretical review. Neuropsychol. Rev. 12, 65–109 (2002). · DOI
  92. Bender, D. M., Paraska, K. K., Sereika, S. M., Ryan, C. M. & Berga, S. L. Cognitive function and reproductive hormones in adjuvant therapy for breast cancer: a critical review. J. Pain Sympt. Manage. 21, 407–424 (2001). · DOI · Paper page
  93. Jenkins, V. A., Bloomfield, D. J., Shilling, V. M. & Edginton, T. L. Does neoadjuvant hormone therapy for early prostate cancer affect cognition? Results from a pilot study. Br. J. Urol. 96, 48–53 (2005). · DOI
  94. Unfer, T. C. et al. Influence of hormone replacement therapy on blood antioxidant enzymes in menopausal women. Clin. Chim. Acta 369, 73–77 (2006). · DOI
  95. Chisu, V., Lepore, M. G., Zedda, M. & Farina, V. Testosterone induces neuroprotection from oxidative stress. Effects on catalase activity and 3-Nitro-L-styrosine incorporation into α-tubulin in a mouse neuroblastoma cell line. Arch. Ital. Biol. 144, 63–73 (2006).
  96. Lee, D.-C., Im, J.-A., Kim, J.-H., Lee, H.-R. & Shim, J.-Y. Effect of long-term hormone therapy on telomere length in postmenopausal women. Yonsei Med. J. 46, 471–479 (2005). · DOI
  97. Theodoulou M. & Seidman, A. D. Cardiac effects of adjuvant therapy for early breast cancer. Semin. Oncol. 30, 730–739 (2003). · DOI
  98. Miller, D. B. & O' Callaghan, J. P. Aging, stress and the hippocampus. Age. Res. Rev. 4, 123–140 (2005). · DOI · Paper page
  99. Hukovic, N. & Brown E. S. Effects of prescription corticosteroids on mood and cognition. Adv. Psychosom. Med. 24, 161–167 (2003). · DOI
  100. Lee, G. D. et al. Transient improvement in cognitive function and synaptic plasticity in rats following cancer chemotherapy. Clin. Cancer Res. 12, 198–205 (2006). · DOI
  101. Winocur, G., Vardy, J, Bims, M. A., Kerr, L. & Tannock, I. The effects of the anti-cancer drugs, methotrexate and 5-fluorouracil, on cognitive function in mice. Pharmacol. Biochem. Behav. 85, 66–75 (2006). These investigators developed an animal model of chemotherapy-induced cognitive deficits and showed deficits in memory and learning tasks in mice treated with chemotherapy that were similar to deficits seen in breast cancer survivors. · DOI

Cited by

See all 916

Metadata

Authors
Ahles, T. A., & Saykin, A. J.
Venue
Nature Reviews Cancer
Publisher
Springer Science and Business Media LLC
Published
2007-03
Volume
7
Issue
3
Pages
192-201
ISSN
  • 1474-175X (ISSN-L)
  • 1474-1768
DOI
10.1038/nrc2073
OpenAlex
W2056804370
Cited by
916
References
6
FWCI
5.02
Type
journal article
Language
en
Open access
green
Licence
www.springer.com/tdm (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.